Clinical Trial Update: SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SHR-1210 in relapsed or refractory extranodal NK/T-cell lymphoma, nasal type.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type

Drugs mentioned

• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Extranodal NK/T-cell Lymphoma, Nasal Type | Phase 2 | Status: UNKNOWN